Literature DB >> 7693845

Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats.

S E Bastian1, P E Walton, J C Wallace, F J Ballard.   

Abstract

To determine whether the changes in insulin-like growth factor-binding proteins (IGFBPs) and IGF-I levels during pregnancy in rats affect the clearance of IGFs from the circulation, we have measured pharmacokinetic parameters and the tissue distribution of radiolabelled IGF-I and LR3IGF-I, a potent analogue which has a markedly reduced affinity of binding to the IGFBPs. Intravenous boluses of radiolabelled growth factors were administered to catheterized virgin and age-matched pregnant rats on day 18 of gestation when plasma IGFBPs, in particular IGFBP-3, are dramatically reduced. IGF-I was cleared more rapidly from plasma in pregnant rats compared with the virgins; metabolic clearance rate (MCR) = 2.88 +/- 0.12 (S.E.M.) and 0.90 +/- 0.05 ml/min per kg respectively. Although LR3IGF-I was cleared more rapidly than IGF-I from plasma, similar clearance rates for the analogue were obtained in both pregnant and virgin animals, MCR = 9.19 +/- 0.15 and 9.84 +/- 0.28 ml/min per kg respectively. In virgin rat plasma, labelled IGF-I was mainly associated with the 150 kDa complex, whereas in pregnant rat plasma IGF-I was predominantly associated with lower M(r) IGFBPs (approximately 30-50 kDa). The majority of LR3IGF-I was detected as free peptide. A larger proportion of the tracer was detected as small M(r) breakdown products in plasma from rats under conditions of reduced binding to IGFBPs, e.g. during pregnancy or when LR3IGF-I was the labelled tracer, suggesting greater rates of IGF degradation. More LR3IGF-I tracer was detected in kidneys, ovaries and adrenals of virgin rats and in the ovaries and adrenals of pregnant rats, compared with IGF-I tracer. IGF-I radioactivity was greater than LR3IGF-I in caecum, brain, liver and heart in virgin rats and in kidneys, caecum, brain, liver, heart, placenta, fetus and fetal plasma of the pregnant rats. These results show that the reduction in IGFBP during pregnancy dramatically increased the clearance of IGF-I from the circulation towards that obtained with LR3IGF-I. The observation that less LR3IGF-I was detected in placenta, fetus and fetal plasma compared with IGF-I raises the possibility that the ability to bind IGFBPs during pregnancy may enhance IGF uptake by the conceptus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693845     DOI: 10.1677/joe.0.1380327

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  5 in total

Review 1.  Insulin-like growth factors: actions on the skeleton.

Authors:  Shoshana Yakar; Haim Werner; Clifford J Rosen
Journal:  J Mol Endocrinol       Date:  2018-04-06       Impact factor: 5.098

2.  Administration of insulin-like growth factor-I (IGF-I) peptides for three days stimulates proliferation of the small intestinal epithelium in rats.

Authors:  C B Steeb; J F Trahair; L C Read
Journal:  Gut       Date:  1995-11       Impact factor: 23.059

3.  Unbound (bioavailable) IGF1 enhances somatic growth.

Authors:  Sebastien Elis; Yingjie Wu; Hayden-William Courtland; Dara Cannata; Hui Sun; Mordechay Beth-On; Chengyu Liu; Hector Jasper; Horacio Domené; Liliana Karabatas; Clara Guida; Jelena Basta-Pljakic; Luis Cardoso; Clifford J Rosen; Jan Frystyk; Shoshana Yakar
Journal:  Dis Model Mech       Date:  2011-05-31       Impact factor: 5.758

4.  Sheep recombinant IGF-1 promotes organ-specific growth in fetal sheep.

Authors:  J Stremming; A White; A Donthi; D G Batt; B Hetrick; E I Chang; S R Wesolowski; M B Seefeldt; C E McCurdy; P J Rozance; L D Brown
Journal:  Front Physiol       Date:  2022-08-25       Impact factor: 4.755

5.  Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations.

Authors:  Joseph A M J L Janssen; Leo J Hofland; Christian J Strasburger; Elisabeth S R van den Dungen; Mario Thevis
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.